This article is more than 5 years old. Information may no longer be current.

FDA approves Nuvail for brittle nails

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The FDA has approved a polymer treatment for nail dystrophy, according to a press release from Innocutis.

Nuvail is a 16% poly-ureaurethane nail solution available in 15-ml bottles recommended for application once a day. It is used to treat the condition characterized by damaged or brittle nails with cracking or splitting.

Brittle nail syndrome affects about 20% of people, with women affected twice as often as men, according to the release from the Charleston, S.C., pharmaceutical and medical device company.

“Patients will have a nail treatment that allows the nail to breathe but is still non-water-soluble and is able to protect the nail from the impact of moisture and friction,” Jonathan Alba, Innocutis chief operating officer, said in the release.